Loading clinical trials...

Modeling Amyotrophic Lateral Sclerosis With Fibroblasts | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGNA

Modeling Amyotrophic Lateral Sclerosis With Fibroblasts

Modeling of Amyotrophic Lateral Sclerosis Using Patient Fibroblasts to Study Different Form of the Disease.

NCT06450691•Assistance Publique - Hôpitaux de Paris

Summary

Amyotrophic Lateral Sclerosis (ALS) is the most common motor neuron disease in adults. This longitudinal study involves three cohorts of participants: patients with sporadic or hereditary ALS, asymptomatic individuals carrying pathogenic mutations responsible for ALS, and control subjects. In this study, a skin biopsy and blood sampling will be performed at the initial visit (M0), then at M12 (+/- 2 months) for patients, and at M36 (+/- 12 months) for asymptomatic carriers of pathogenic mutations. The aim of this research is to model ALS pathology using fibroblasts derived from the patients' skin biopsies.

Detailed Description

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•adults, both sexes
•with written consent to participate in the study
•affiliated to a social security scheme
•ALS patients :
•patients with ALS according to the revised El Escorial criteria :
•with a hereditary form of ALS, defined by the presence of a family history of ALS or by the demonstration of a pathogenic mutation in the patient or
•with a juvenile form of the disease, defined by onset of symptoms at less than 30 years of age or
•with a sporadic form of ALS
•Asymptomatic mutation carriers :
•\- Asymptomatic individuals who carry a mutation causing ALS but have not developed symptoms.
+2 more criteria

Exclusion Criteria

•with a known skin disease (acne, atopic dermatitis, psoriasis, melanoma, skin carcinoma, rosacea, scabies; as referenced on http://dermato-info.fr/), which in the investigator's opinion constitutes a contraindication to skin biopsy
•have a platelet count of less than 75,000/mm3 in a laboratory test less than 3 months old,
•with a proven allergy to lidocaine or prilocaine,
•Pregnant or breast-feeding women, or subjects under guardianship, curatorship or safeguard of justice.
•Patient's condition which, in the opinion of the investigator, is incompatible with skin sampling or participation in the study.
•Participation in a clinical trial (involving a drug) or other interventional research if this interferes with FIBRALS research.

Locations (1)

CIC Neurosciences

Paris, France

Key Dates

Start Date

September 1, 2024

Primary Completion Date

September 1, 2033

Completion Date

September 1, 2033

Last Updated

July 3, 2024

Enrollment

110

ESTIMATED participants

Conditions

Amyotrophic Lateral Sclerosis

Interventions

biopsy

PROCEDURE

Contacts

Maria del Mar Amador, MD

CONTACT

33142162472 mariadelmar.amador@aphp.fr

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

NCT07322003

Amyotrophic Lateral Sclerosis

View study

RECRUITING

Intermuscular Coherence as a Biomarker for ALS

NCT05104710

Amyotrophic Lateral Sclerosis

View study

RECRUITING

UPenn Observational Research Repository on Neurodegenerative Disease

NCT04715399

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 3, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Modeling Amyotrophic Lateral Sclerosis With Fibroblasts

Inclusion Criteria

Exclusion Criteria

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

Intermuscular Coherence as a Biomarker for ALS

UPenn Observational Research Repository on Neurodegenerative Disease

Connect-One: Early Feasibility Study of Connexus® Brain-Computer Interface (BCI)

Control Cohort CTRL COH

ASSESS ALL ALS Study